Sign In
Last checked at 
30 Mar 2020 07:00
ValiRx Plc
("ValiRx" or the "Company")
Update
London, UK. 30 March 2020: ValiRx Plc (AIM: VAL), a clinical stage biotechnology company, provides the following update:-
The Company remains critically short of working capital and as previously stated is dependent on the ongoing support of its creditors in order to continue trading.
The Company adjourned its General Meeting which was to be held on 25 March 2020 as a result of the COVID-19 situation.
The Company is reviewing options available to it in order to reconvene the meeting, bearing in mind the current restrictions on public gatherings.
The Company is in discussions with a number of potential funders who have indicated conditional willingness to invest in the Company in the event that resolutions are passed.
There is no guarantee that resolutions will be passed by shareholders at the General Meeting or that funding will ultimately be available to the Company or that creditors will be willing to extend their support to enable potential funding to occur. A further announcement will be made in due course.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For more information, please contact:
ValiRx plc | Tel: +44 (0) 20 7073 2628 www.valirx.com |
Dr Satu Vainikka, Chief Executive | Tel: +44 (0) 20 7073 2628 |
Tarquin Edwards, Head of Communications. | Tel: +44 (0) 7879 458 364 tarquin.edwards@valirx.com
|
Cairn Financial Advisers LLP - Nominated Adviser
|
|
Liam Murray / Jo Turner
| Tel: +44 (0) 20 7213 0880 |
|
|
Follow the stocks
